乐观
$27.96
情景价格
$23.800
+1.264 (+5.31%)收盘时
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.
Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Schrödinger to Report Q3 2026 Financial Results on November 4

New Study Reveals Multi-Lithium Ion Clustering in Battery Electrolytes

Schrodinger Inc Stock Surpasses Analyst Target Price

MindWalk Secures $30 Million Unsecured Credit Facility

Schrödinger Grants Restricted Stock Units to New Employees
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities. It operates in the Technology sector (PHARMACEUTICAL PREPARATIONS industry).
Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。